Fresh Equities



Data provided by Weblink | as of last close

OPTHEA LIMITED has not announced any current capital raises, but we are collecting interest for future raises.

Demand Registered for Next Raise
< $50k
Investors Interested in Next Raise
< 10
How Fresh Equities Works

1. Create Account

Complete your onboarding digitally in less than 3 minutes.


2. View Terms

View the full term sheet for the capital raise.


3. Bid for Allocation

Submit and track your bid online.

Capital Raise History

1 December 2019

Offer Price
Price at Close
Market Cap

Company Overview

Opthea Limited (ASX:OPT) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around VEGF-C, VEGF-D and VEGFR-3. Opthea’s intellectual property is held within its wholly-owned subsidiary Vegenics Pty Ltd. Opthea’s product development programs are focused on developing OPT-302 for retinal eye diseases including wet Age-related Macular Degeneration and Diabetic Macular Edema (DME). OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule that blocks the activity of two proteins (VEGF- C and VEGF-D) that cause blood vessels to grow and leak, processes which contribute to the pathophysiology of retinal diseases. Opthea is developing OPT-302 for use in combination with inhibitors of VEGF-A and has reported outcomes from an international, multi-centre, prospective, sham-controlled, double-masked, superiority study that enrolled 366 treatment-naïve patients with wet AMD. Participants in the study were randomized in a 1:1:1 ratio to receive one of the following treatment regimens administered every 4 weeks for 24 weeks: OPT-302 (0.5 mg) in combination with ranibizumab (Lucentis®) (0.5 mg); OPT-302 (2.0 mg) in combination with ranibizumab (0.5 mg); or sham in combination with ranibizumab (0.5 mg). The study met the primary endpoint demonstrating superior vision gains in participants who received OPT-302 (2.0 mg) in combination with ranibizumab on a monthly basis over 6 months. Opthea is also investigating OPT-302 in a Phase 2a clinical trial in patients with persistent, centre-involved DME. Further details on the Company’s clinical trials can be found at:, Clinical trial identifiers: NCT02543229, NCT03345082 and NCT03397264.


Listed Company

GICS Sub-industry


Head Office

Unit 4/650 Chapel St, South Yarra VIC 3141, Australia

Health Care
Biotech & Health

Price Chart

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.



Fresh Equities does not have OPTHEA LIMITED directors data.


All Time
    Ceasing to be a substantial holder on 16 January 2020

    Shareholder Details

    Becoming a substantial holder on 9 January 2020

    Shareholder Details

  • Opthea Completes Recruitment in Ph2a Trial of OPT-302 in DME on 6 January 2020

    Progress Report

  • Ceasing to be a substantial holder on 16 December 2019

    Shareholder Details

    Becoming a substantial holder on 12 December 2019

    Shareholder Details

    Change in substantial holding on 10 December 2019

    Shareholder Details

    Ceasing to be a substantial holder on 10 December 2019

    Shareholder Details

    Completion of A$50 million Institutional Placement on 5 December 2019

    Issued Capital

    Becoming a substantial holder on 5 December 2019

    Shareholder Details

    Appendix 3B on 1 December 2019

    Issued Capital

    Load More


Fresh Equities does not have OPTHEA LIMITED news data.